Retatrutide Explained: Triple Agonist Peptide (GLP-1/GIP/Glucagon) Science

By Justin Cartier

For the wider context, see our overview of research peptides for weight loss.

Retatrutide is a once-a-week injectable peptide that flips on three gut-hormone receptors at the same time: GLP-1, GIP, and glucagon. And the numbers are eye-opening. In a Phase 2 trial it produced about 24 percent average body-weight loss at the top dose over 48 weeks, the biggest reported for any peptide in this class.^[1]

This article is for research and educational use only. Retatrutide is an experimental research compound. It isn’t approved for human use, and nothing here is medical advice.

The surprising piece is that third receptor, glucagon. Glucagon normally raises blood sugar, so bolting it onto a diabetes-style drug sounds completely backwards. But here’s the trick: at the doses retatrutide uses, the GLP-1 and GIP parts hold blood sugar in check while the glucagon part quietly burns more energy and fat. You end up with extra weight loss and no blood-sugar penalty. Whether that balance holds in bigger, more varied groups of people is exactly what the Phase 3 TRIUMPH trials are out to test.

This guide covers how retatrutide’s triple-receptor action stacks up against semaglutide and tirzepatide, what the Phase 2 data show on weight, liver fat, blood sugar, and side effects, the Phase 3 timeline, and where it stands today. Every claim links to a primary source.

What does retatrutide do and how does it work?

It works by switching on three gut-hormone receptors at once: GLP-1, GIP, and glucagon. Under the hood it’s a 39-amino-acid lab-made peptide, built specifically to hit all three. Coskun and colleagues at Eli Lilly, in Cell Metabolism, describe LY3437943 as a triple agonist at the glucagon, GIP, and GLP-1 receptors, engineered to blend GLP-1’s appetite control, GIP’s insulin boost, and glucagon’s energy burning.^[2]

That triple action is the whole design bet. Where single receptor agonists pull one lever, retatrutide pulls three at once. GLP-1 on its own lowers appetite and drives fat loss. Add GIP, like tirzepatide does, and the reduction goes further. Add the glucagon receptor and now you’ve got active energy burning on top. Conceição-Furber and colleagues, in Frontiers in Endocrinology, lay out how turning on the glucagon receptor lifts energy use enough to open a calorie deficit even without any extra appetite suppression.^[3]

One more clever bit: it’s been tweaked at one end to survive longer in the body. Deacon and colleagues, in Diabetologia, showed years ago that altering the end of a GLP-1 peptide makes it resist the DPP-4 enzyme, and that same principle is why retatrutide only needs a once-a-week shot under the skin.^[4]

How much weight loss does retatrutide produce?

Up to about 24 percent in the Phase 2 trial, which is a lot for adults with obesity, and the efficacy and safety held together across the whole dose range. Jastreboff and colleagues, in the New England Journal of Medicine, reported that 48 weeks of treatment cut body weight by 8.7 percent at 1 mg, 17.1 percent at 4 mg, 22.8 percent at 8 mg, and 24.2 percent at 12 mg, all once a week under the skin.^[1] At the 12 mg dose, nearly everyone lost at least 5 percent of their body weight.

Put that in context. Semaglutide‘s STEP-1 trial landed at 14.9 percent over 68 weeks, and tirzepatide‘s SURMOUNT-1 hit 20.9 percent at its top dose over 72 weeks. Retatrutide reached 24.2 percent in a shorter 48 weeks, which hints that the triple action may genuinely raise the ceiling on drug-based weight reduction.

Hepatic fat and metabolic measures

It hammered liver fat, too. Sanyal and colleagues, in Nature Medicine, found liver fat dropping by 80 to 90 percent over 48 weeks in patients who started with fatty liver disease, and the drop tracked closely with changes in body weight and belly fat.^[5] Blood sugar control, blood pressure, and triglycerides all improved right alongside it.

The liver result is a bit of a plot twist, honestly, because the glucagon part should in theory bump up the sugar the liver makes. In practice the GLP-1 and GIP parts win the tug-of-war, so blood sugar control gets better with retatrutide, not worse.

Is retatrutide better than Ozempic?

For raw weight loss, the data so far puts retatrutide out ahead of Ozempic, 24.2 percent at 12 mg over 48 weeks versus 14.9 percent at 2.4 mg over 68 weeks for semaglutide. The cleanest way to see the family is by receptor count. Ozempic and Wegovy, both semaglutide, hit one receptor, GLP-1. Mounjaro and Zepbound, both tirzepatide, hit two, GLP-1 plus GIP. Retatrutide hits three, adding glucagon. So “better” really depends on your goal. For pure weight loss, retatrutide leads the data. For something you can actually get today, semaglutide and tirzepatide are the approved options. And on side effects, the two- and three-receptor drugs tend to bring a bit more stomach upset than semaglutide alone at the top doses.

Retatrutide vs tirzepatide

These two are cousins, both Eli Lilly drugs in the same family. Tirzepatide, sold as Mounjaro and Zepbound, is the approved two-receptor drug; retatrutide is the experimental three-receptor version that adds glucagon. That extra receptor is what gives retatrutide an energy-burning effect tirzepatide simply doesn’t have. There’s no head-to-head Phase 3 data yet, but the Phase 2 numbers suggest retatrutide takes off more weight at the same total dose. The side effects look similar in shape, with nausea and stomach symptoms leading the pack for both.

Dosage and administration schedule

Phase 2 ran retatrutide once a week under the skin at 1, 4, 8, and 12 mg, starting at 2 mg and climbing every 4 weeks. The Phase 3 TRIUMPH program uses a similar step-up, targeting 6, 8, and 12 mg. The 8 and 12 mg groups shed the most weight but paid for it with the most stomach side effects, while the 4 mg group was easier to tolerate and still worked well. In practice, the right dose of retatrutide comes down to a balance between how much weight comes off and how comfortably the retatrutide treatment is tolerated, which is exactly the kind of trade-off the late trials are meant to pin down.

Side effects and who should not take retatrutide

Stomach trouble tops the list. In Phase 2 that meant nausea, vomiting, diarrhea, and constipation, with 6 to 16 percent of people stopping depending on dose. Beyond that, there were injection-site reactions, headache, and the small, steady rise in heart rate you see across this whole drug class. The glucagon part raises a theoretical flag about insulin sensitivity and liver sugar, but again, the published data doesn’t show meaningful high blood sugar.

As for who should steer clear, and this is still being worked out, the likely list matches the rest of the class: anyone with a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe stomach-emptying problems, severe diabetic eye disease, or pregnancy. People with type 1 diabetes or uncontrolled type 2 shouldn’t use it outside a monitored research setting.

When will retatrutide be available in Canada?

Not yet, and not anywhere. Health Canada, the FDA, and every other major regulator have yet to approve it. The Phase 3 TRIUMPH program kicked off in 2022, with key results expected through 2026 and 2027. If those late trials keep matching the Phase 2 story, approval in Canada and the US could land around 2027 or 2028. Until then, research-grade retatrutide is sold in Canada and the United States only as a research chemical for laboratory use.

Cost expectations and clinical trial access

If it clears approval, retatrutide will probably price out near tirzepatide and semaglutide, somewhere around CAD 400 to 600 a month at retail, with insurance likely following the same path as the other obesity drugs. Right now, joining the TRIUMPH trials is the main legal route to access it in Canada, and the trial sites are listed at clinicaltrials.gov.

Other health conditions beyond weight loss

Weight loss is only part of the story. The Phase 2 program also looked at type 2 diabetes, fatty liver disease, and high blood pressure, and the results were strong across the board: HbA1c dropped 1.5 to 2.0 points at the top doses, liver fat fell 80 to 90 percent, and blood pressure eased in line with the rest of the class. Late trials are even checking heart outcomes now. That breadth is exactly what makes retatrutide such a useful research tool, letting scientists probe the triple-receptor action across many endpoints, not just the scale.

Legal status

Retatrutide is still investigational everywhere, with the Phase 3 TRIUMPH program ongoing, so until a regulator clears it, it can only be handled as a research chemical; the Canadian legal framework for research peptides covers the research-use rules that apply.

Quality varies widely between sellers, so order peptides in Canada from one that publishes purity data.

What an unverified batch does to your data

Retatrutide is a 39-amino-acid peptide near 4,731 Da, and its design leans on two fragile details: a modified end that resists the DPP-4 enzyme so it can last a week, and three separate binding regions balanced across the GLP-1, GIP, and glucagon receptors. Both are easy to lose in a bad batch. A truncated contaminant that dropped the protected end gets chewed up by DPP-4 and cleared in hours, so a once-weekly pharmacokinetic study quietly turns into a short-acting one and the timing data comes out wrong. Worse, a deletion at one of the three binding regions can turn the triple agonist into a weaker dual or single agonist, and if the glucagon arm is thrown out of balance, a glucose or energy-expenditure assay can even read backwards, with glucagon pushing blood sugar up instead of the clean metabolic profile you expected. A silently degraded, under-strength vial just looks like low potency, and endotoxin adds inflammatory noise on top of the metabolic readouts. Mass spectrometry confirming the ~4,731 Da identity, HPLC purity from a batch-specific Certificate of Analysis, and endotoxin plus sterility testing for live-animal or cell-culture work are what keep those failures out of the data.^[6]

Reviv Peptides supplies research-grade retatrutide with third-party COA and HPLC purity confirmation, and researchers can buy Retatrutide in Canada with a batch COA included.

Retatrutide questions

What does retatrutide do to your body and how does it work?

It turns on three receptors at once: GLP-1, GIP, and glucagon. That lowers appetite, slows the stomach, raises insulin, and burns more energy through the glucagon part. The net result is large weight loss and better blood sugar control.

Is retatrutide more effective than Ozempic?

For weight loss, the data puts retatrutide ahead: 24.2 percent at 12 mg over 48 weeks versus 14.9 percent for semaglutide at 2.4 mg over 68 weeks. But semaglutide is approved and available now, while retatrutide is still in Phase 3.

When will retatrutide be available in Canada?

Not yet. Phase 3 TRIUMPH results are expected in 2026 and 2027, and Health Canada approval is likely in 2027 or 2028 if the late data holds up.

Who should not take retatrutide?

The likely groups to avoid it, still being studied, include people with a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe stomach-emptying problems, type 1 diabetes, or pregnancy. It isn’t meant for unmonitored use outside clinical trials.

How much weight can someone expect to lose with retatrutide?

Phase 2 data: 8.7 percent at 1 mg, 17.1 percent at 4 mg, 22.8 percent at 8 mg, and 24.2 percent at 12 mg over 48 weeks. The amount depends on dose, and it beats both semaglutide and tirzepatide at the same total exposure.

Key data point: in the retatrutide fatty-liver study, Sanyal and colleagues (Nature Medicine, 2024) reported liver fat falling 80 to 90 percent over 48 weeks in patients who started with fatty liver disease, a drop tied closely to the weight and belly-fat loss and, in theory, to glucagon-receptor-driven fat burning in the liver.^[5]

Summary

Retatrutide, or LY3437943, is the first three-receptor peptide in this class to reach late trials, hitting GLP-1, GIP, and glucagon receptors all at once. Phase 2 data shows 24.2 percent weight loss over 48 weeks at the 12 mg dose, the largest reported for any peptide in the class. It gets there by combining appetite control from GLP-1, an insulin boost from GIP, and energy burning from glucagon. The Phase 3 TRIUMPH program is underway, and approval is plausible in 2027 or 2028. Until then it stays investigational and is handled as a research chemical only.

Sources: [1] Phase 2 obesity trial of retatrutide, PubMed. [2] LY3437943 triple agonist pharmacology, PubMed. [3] Glucagon receptor activation and energy expenditure, PubMed. [4] DPP-IV-resistant GLP-1 analogues, PubMed. [5] Retatrutide for liver fat / MASLD, PubMed. [6] HPLC and mass-spectrometry quality control of synthetic peptides, PMC/NIH.